Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway.
The aim of the present study was to investigate the role of the entitled neutral, sphingomyelinase in the non-lysosomal pathway of sphingomyelin degradation by intact cells (Spence et al. (1983) J. Biol. Chem. 258, 8595-8600; Levade et al. (1991) J. Biol. Chem. 266, 13519-13529). The uptake and degradation of sphingomyelin by intact living cells was studied using cell lines exhibiting a wide range of activity levels of acid, lysosomal and neutral sphingomyelinases as determined in vitro on cell homogenates by their respective standard assays. For this purpose, neuroblastoma, skin fibroblasts, lymphoid and leukemic cell lines, some of them derived from patients with Niemann-Pick disease (deficient in the acid, lysosomal sphingomyelinase) were incubated with radioactive, [oleoyl-3H]sphingomyelin or fluorescent, pyrene-sulfonylaminoundecanoyl-sphingomyelin. Either compound was taken up by a pathway which was not receptor-mediated and hydrolyzed by all intact cells, including those derived from Niemann-Pick disease patients. Moreover, their degradation by the intact cells was not inhibited by treatment with chloroquine, indicating hydrolysis by a non-lysosomal sphingomyelinase. The intracellular sphingomyelin degradation rates showed no correlation with the activity of the 'classical' neutral sphingomyelinase as determined in vitro. In particular, fibroblasts derived from Niemann-Pick patients lacking the lysosomal sphingomyelinase, and having no detectable in vitro activity of the 'classical' neutral sphingomyelinase, were able to degrade the exogenously supplied sphingomyelins. Indeed, in vitro these cells were shown to exhibit neutral, magnesium- and dithiothreitol-dependent sphingomyelinase activities, that might contribute to the non-lysosomal pathway for sphingomyelin degradation to ceramide in intact cells.
Levade
T
T
Laboratoire de Biochimie, CJF INSERM 9206, Institut Louis Bugnard, C.H.U. Rangueil, Toulouse, France.
Vidal
F
F
Vermeersch
S
S
Andrieu
N
N
Gatt
S
S
Salvayre
R
R
D001952:Bridged-Ring Compounds / Q000494:pharmacology; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D004705:Endocytosis; D005456:Fluorescent Dyes; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D008247:Lysosomes / Q000201:enzymology / Q000378:metabolism; D008274:Magnesium / Q000378:metabolism / Q000494:pharmacology; D009542:Niemann-Pick Diseases / Q000378:metabolism; D009636:Norbornanes; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013109:Sphingomyelins / Q000378:metabolism*; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D015032:Zinc / Q000494:pharmacology
D001952:Bridged-Ring Compounds; D005456:Fluorescent Dyes; D009636:Norbornanes; D010726:Phosphodiesterase Inhibitors; D013109:Sphingomyelins; D013859:Thiocarbamates; D013871:Thiones; C046498:tricyclodecane-9-yl-xanthogenate; D002738:Chloroquine; D004492:Edetic Acid; D013108:Sphingomyelin Phosphodiesterase; D008274:Magnesium; D015032:Zinc; D004229:Dithiothreitol